PHA Production Patents: Who Leads, Where the Gaps Are 2026
A patent landscape review of polyhydroxyalkanoate (PHA) production: filing trends since 2015, leading assignees, technology composition across fermentation and polymer classes, and the white space still open to new filer
Filing growth = 2021 (33 records) → 2024 (28); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 233 records in scope (CR5), not the ranked leaders only.
What the PHA production patent record actually shows
Polyhydroxyalkanoate (PHA) production sits at the intersection of microbial fermentation and polymer chemistry: a producer strain is fed a carbon source, accumulates PHA granules intracellularly, and the polymer is then extracted and formulated into a usable bioplastic. Patent activity in this dataset spans 233 published records filed between 2015 and the 2026 cut-off, covering everything from feedstock and strain engineering to extraction, blending and shaping into finished parts. The representative filing below, a bioplastic-extraction process from a bacterial cell system, illustrates a common claim shape in the field: a biological upstream step paired with a physical downstream separation step in the same application.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend undercount actual filing activity. Treat the 2021 peak as the clearest read on filing intensity so far, and treat 2024 as the last year that can be read as materially complete.
Filing trend, concentration and technology mix
Three figures anchor how to read this field: how filing volume has moved since 2015, how concentrated ownership is among the ranked assignees, and which IPC subclasses carry the claim weight.
Filing trend: growth cooled off its 2021 peak, not off a cliff
Annual filings rose from zero recorded in 2017 to a peak of 33 in 2021, then eased to 28 by 2024 — a -15% move over that three-year span. That is a plateau after a growth phase, not a downturn: 2025 and 2026 figures will revise upward as later publications surface.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition: polymer chemistry outweighs the biology
C08L (polymer compositions) appears on 38.2% of the 233 records, ahead of C12P fermentation and enzymatic synthesis at 28.3% and C08G condensation polymers at 25.8%. C12N, covering the microorganisms and genetic engineering that actually produce the polymer, sits lower at 18.0% — more filings claim what to do with the polymer once made than claim the organism that makes it.
Shares are the percentage of the 233 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biopolymers & Biodegradable Plastics: Polyhydroxyalkanoate Production Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about biopolymers & biodegradable plastics: polyhydroxyalkanoate production patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art and a representative recent filing
Process for extraction of bioplastic and production of monomers from the bioplastic (US20170253713A1, BIOEXTRAX AB)
The present invention relates to a process for extraction of bioplastic from bioplastic-producing microbial cells, comprising the steps of: A. providing bioplastic producing microbial cells comprising bioplastic; B. providing bacterial cells selected from the species Bacillus pumilus; C. extracting the bioplastic by admixing the bioplastic-producing microbial cells of step A and the bacterial cells of step B and allowing reaction. The present invention further relates to the process of producing monomers from said bioplastics by depolymerization.Filed by BIOEXTRAX AB, 2017-09-07 — a two-stage claim pairing a biological extraction agent with downstream monomer recovery, typical of how extraction-stage innovation gets claimed separately from strain and formulation work.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1998051812A2 | Polyhydroxyalkanoates for in VIVO applications | 156 |
| 2 | US7244442B2 | Method for making devices using polyhydroxyalkanoate having pyrogen removed | 140 |
| 3 | US20120149844A1 | Toughened Polyhydroxyalkanoate Compositions | 62 |
| 4 | US6191203B1 | Polymer blends containing polyhydroxyalkanoates and compositions with good retention of elongation | 60 |
| 5 | WO2016058097A1 | Biodegradable polymer filament | 52 |
| 6 | WO1999023161A2 | Polymer blends containing polyhydroxyalkanoates and compositions with good retention of elongation | 46 |
| 7 | WO2011045625A1 | Using cell debris generated from PHA recovery for enhanced cell growth and biopolyester formation | 38 |
| 8 | WO2010118041A1 | Method of improving film processing and injection molding of polyhydroxyalkanoate polymers | 33 |
| 9 | US20010009769A1 | Polyhydroxyalkanoates for in vivo applications | 33 |
| 10 | US20140366765A1 | Degradable shotgun wad | 32 |
Citation counts accumulate over time, so older records such as the two leading this table are structurally favoured; read them as markers of foundational influence, not of current filing activity.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the concentration and the gaps
The ranking, the receiving-office spread and the citation table together point to where PHA production patent risk is dense and where it is thin.
Ownership is concentrated but not closed
The top 5 assignees hold 36.9% of all 233 records and the top 10 hold 57.1%. That leaves close to half the field spread across a long tail of single- or few-filing entrants, which is where a well-targeted claim can still find open ground rather than colliding with an incumbent portfolio.
A plateau, read correctly
Filings rose to 33 in 2021 and eased to 28 by 2024, a -15% move over that span. Given the roughly 18-month publication lag, that is the shape of a maturing field settling into a steady filing rate, not evidence that interest in PHA production is fading.
Formulation claims outnumber organism claims
C08L (polymer compositions) covers 38.2% of the 233 records, more than double the 18.0% carrying C12N microorganism and genetic-engineering claims. Downstream blending, toughening and stabilising work is comparatively crowded; upstream strain and pathway engineering claims are thinner on the ground.
Europe is the busiest single office
The EPO leads with 45 records, just ahead of the United States and WIPO (PCT) at 37 each, with India, Australia and Canada some way behind. A filing strategy built only around the US or PCT route would miss where a meaningful share of prior art actually sits.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biopolymers & biodegradable plastics: polyhydroxyalkanoate production patent landscape, with the prior art for and against each one.
Turning this landscape into a filing or freedom-to-operate decision
A landscape summary tells you where the crowd is; the next step is checking a specific claim or strain against it.
Map a candidate claim against the ranked assignees
Run a proposed strain, extraction method or formulation claim against the concentration pattern here to see whether it lands inside a dense cluster held by a top-10 assignee or in the thinner long tail.
Explore claim-level analysis in EurekaTrack the organism-engineering gap
C12N claims sit well below C08L and C12P in this dataset. If your work is on the producing organism rather than the downstream polymer, that gap is worth watching for both freedom-to-operate and filing opportunity.
Set up a monitoring search in EurekaCheck citation-heavy prior art before drafting
The most-cited records in this field date from earlier filing years and still anchor examiner search reports. Clearing them explicitly in a new application reduces rejection risk.
Review cited prior art in EurekaCommon questions on PHA production patents
This dataset covers 233 published records filed between 2015 and the 2026 cut-off, matched against fermentation, genetic-engineering and biodegradable-polymer claim language. That figure counts patent families, which is the fairer unit than raw document counts because it neutralises repeated continuation filings and multiple jurisdictional copies of the same invention. It is not a count of every PHA-related patent ever filed worldwide, only those captured by this search definition and date range.
The ranked assignee table lists 100 companies, with the leader holding 28 records and the top 5 combined accounting for 36.9% of all 233 records in scope. The top 10 together hold 57.1%, meaning ownership is concentrated at the top but leaves a substantial long tail of smaller filers. Assignee names such as Metabolix, Novamont, Danimer Scientific and CJ CheilJedang appear among the more active filers in this space, alongside research-institution and cooperative filers.
Filings rose from effectively zero in 2017 to a peak of 33 in 2021, then eased to 28 by 2024 — a -15% change over that three-year span. Because patent publication typically lags filing by around 18 months, 2025 and 2026 figures in any such dataset are understated and will revise upward as later filings publish. Read the recent plateau as a maturing filing pace rather than declining interest in the technology.
Polymer compositions (IPC class C08L) appear on 38.2% of the 233 records, the single largest technology share, followed by fermentation and enzymatic synthesis (C12P) at 28.3% and condensation polymers (C08G) at 25.8%. Claims on the producing microorganisms and genetic engineering (C12N) trail at 18.0%, and shaping, layering and sterilising steps make up smaller but still meaningful shares. This mix shows more claim density on what happens to the polymer after fermentation than on engineering the organism itself.
The C12N organism-engineering share, at 18.0% of records, is noticeably thinner than the C08L polymer-composition share at 38.2%, suggesting more room around strain and pathway claims than around downstream formulation claims. The long tail below the top 10 assignees, who together hold 57.1% of the 233 records, also indicates space outside the most concentrated portfolios. Any specific claim should still be checked against the most-cited prior art in the field before drafting, since several foundational filings there remain actively cited.
Research Biopolymers & Biodegradable Plastics: Polyhydroxyalkanoate Production Patent Landscape in depth with Eureka
Go past this page: query the whole biopolymers & biodegradable plastics: polyhydroxyalkanoate production patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.